MedTech Revenue Hits $325B in H1 2026 as M&A Jumps 160%, EY Says
Image
New York – October 19, 2026 -- Global MedTech M&A value rose 160% in the first half of 2026 versus the same period of 2025, with total disclosed deal value reaching roughly US$130 billion, the highest level in more than a decade, according to the 20th edition of EY US's Pulse of the MedTech Industry report.
The recovery is narrow. EY found it was driven by a limited number of blockbuster transactions rather than broad-based dealmaking.
Industry revenue reached $325 billion in the first half of 2026, up 7.1%
MedTech generated approximately US$650 billion in revenue in 2025, growth of 11%. First-half 2026 revenue of US$325 billion was 7.1% above the prior-year period. Therapeutic devices led growth, followed by non-imaging diagnostics, imaging, and lab equipment and tools.